Finally, promising evidence supports the use of CD19 CAR-T cell therapy in RUNX1-mutated blast-phase chronic myeloid leukemia (BP-CML), a high-risk condition with poor prognosis. This evidence concerns the gene RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive.